Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

PHASE4CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

September 3, 2025

Study Completion Date

September 3, 2025

Conditions
Cough-Variant Asthma
Interventions
DRUG

Budesonide-Formoterol treatment

Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID

Trial Locations (39)

100029

Research Site, Beijing

100034

Research Site, Beijing

117000

Research Site, Benxi

201114

Research Site, Shanghai

211100

Research Site, Nanjing

230011

Research Site, Heifei

261000

Research Site, Weifang

264000

Research Site, Yantai

274400

Research Site, Heze

310000

Research Site, Shanghai

314001

Research Site, Jiaxing

321000

Research Site, Jinhua

325000

Research Site, Wenzhou

325027

Research Site, Wenzhou

330006

Research Site, Nanchang

350005

Research Site, Fuzhou

362000

Research Site, Quanzhou

400000

Research Site, Chongqing

411228

Research Site, Xiangtan

450000

Research Site, Zhengzhou

473000

Research Site, Nanyang

476100

Research Site, Shangqiu

510000

Research Site, Guangzhou

510163

Research Site, Guangzhou

510515

Research Site, Guangzhou

516002

Research Site, Huizhou

518020

Research Site, Shenzhen

545006

Research Site, Liuzhou

550002

Research Site, Guiyang

563100

Research Site, Zunyi

610014

Research Site, Chengdu

610041

Research Site, Chengdu

657299

Research Site, Suzhou

710006

Research Site, Xi'an

CN-523326

Research Site, Dongguan

032299

Research Site, Fenyang

050001

Research Site, Shijiazhuang

030001

Research Site, Taiyuan

030032

Research Site, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY